Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Coeptis Therapeutics Holdings Inc | COEP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.40 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.40 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.03 - 8.7551 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.40 | USD |
Coeptis Therapeutics Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 7.16M | 5.12M | 1.51M | $ 75.00k | $ - | -0.66 | -0.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 4.18M | - |
Coeptis Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COEP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.4365 | 1.55 | 1.19 | 1.37 | 79,803 | -0.0365 | -2.54% |
| 1 Month | 1.48 | 1.8211 | 1.19 | 1.54 | 115,545 | -0.08 | -5.41% |
| 3 Months | 1.63 | 2.03 | 1.19 | 1.59 | 109,556 | -0.23 | -14.11% |
| 6 Months | 8.20 | 8.7551 | 1.03 | 1.85 | 97,008 | -6.80 | -82.93% |
| 1 Year | 8.20 | 8.7551 | 1.03 | 1.85 | 97,008 | -6.80 | -82.93% |
| 3 Years | 8.20 | 8.7551 | 1.03 | 1.85 | 97,008 | -6.80 | -82.93% |
| 5 Years | 8.20 | 8.7551 | 1.03 | 1.85 | 97,008 | -6.80 | -82.93% |
Coeptis Therapeutics Description
| Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio comprises multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet. |